Further examination with multivariate regression revealed that the initial severity of generalized anxiety disorder (GAD) was the only factor linked to a notable improvement in anxiety symptoms. In recent years, cannabis-based medicinal products (CBMPs) have presented a new pharmacotherapeutic approach to treating generalized anxiety disorder (GAD) and sleep disturbances, offering an alternative for those who might not respond well to traditional treatments. Individuals diagnosed with both GAD and insomnia find it more difficult to respond to treatment, leading to an exacerbation of anxiety symptoms and worsening social and mental well-being. GAD affects millions of people worldwide, often leading to a diminished quality of life and creating a greater socioeconomic burden on society. The study recorded changes in PROMs from baseline to 1, 3, 6, and 12 months as patients continued their treatment with medical cannabis.Of the 302 patients who participated in the study, mean index values improved at all time points.
In recent years, cannabis-based medicinal products (CBMPs) have presented a new pharmacotherapeutic approach to treating generalized anxiety disorder (GAD) and sleep disturbances, offering an alternative for those who might not respond well to traditional treatments.
GAD affects millions of people worldwide, often leading to a diminished quality of life and creating a greater socioeconomic burden on society. Many patients with GAD experience symptoms such as restlessness, difficulty concentrating, and sleep disturbances – which can significantly impact their daily lives.
While current pharmacological treatments...
Read the full article @ Marijuana Index